Navigation Links
Gemin X Announces Publication of Preclinical Data of GX15-070 in,Multiple Myeloma in Blood

MONTREAL & MALVERN, Pa.--(BUSINESS WIRE)--Mar 7, 2007 - Gemin X announced today that a report published in the online version of the journal Blood demonstrated that its lead compound, GX15-070 (obatoclax), induced potent cytotoxic responses against patient-derived multiple myeloma tumor cells as a single-agent, and enhanced anti-myeloma effects when used as a combination therapy. GX15-070 is a small molecule specifically designed to inhibit all relevant members of the Bcl-2 protein family, a validated cancer target, restoring the natural cell death process of apoptosis.

"The ability of GX15-070 to inhibit tumor progression and also enhance the effects of other treatment modalities that often suffer from resistance is encouraging," stated Gordon Shore, Ph.D., Chief Scientific Officer of Gemin X. "This study describes the novel activity of this compound and supports its therapeutic use in diverse cancer types, including multiple myeloma."

In the preclinical studies, GX15-070 potently inhibited the viability of 15 of 16 human myeloma cell lines (HMCLs), including those resistant to treatment with melphalan (a chemotherapeutic) and dexamethasone (a corticosteroid). Combination studies with GX15-070 demonstrated that it enhanced the anti-myeloma activity stimulated by melphalan, dexamethasone, and bortezomib, a proteosome inhibitor. Additionally, single-agent studies of the candidate showed that it induced potent cytotoxic responses against patient-derived tumor cells without inducing cytotoxicity to human blood lymphocytes.

Gemin X is currently conducting several clinical trials of GX15-070 in multiple cancer types as a combination therapy and as a single agent. Gemin X recently initiated a Phase 1 trial with GX15-070 in combination with bortezomib in patients with mantle cell lymphoma (MCL) and a Phase 1/2 clinical trial in combination with docetaxel in patients with non-small cell lung cancer. G
'"/>




Page: 1 2

Related medicine technology :

1. Gemin X Biotechnologies Announces Publication in Blood of Positive Preclinical Data of Lead Compound in Mantle Cell Lymphoma
2. Gemin X Presents Positive Preclinical Data of GX15-070 in Infant ALL at AACR Meeting
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:8/21/2014)... FLORHAM PARK, N.J. , Aug. 21, 2014 ... specialty pharmacy group purchasing organization (GPO), is pleased ... (Aurora) to collaborate on a host of innovative ... will help Aurora deliver enhanced therapy management services ... Therapy Management (OTM) system. Aurora will ...
(Date:8/21/2014)... HOUSTON , Aug. 21, 2014 ... innovation in paediatric medicine by awarding the three ... Paediatric Formulation initiative (EuPFI) conference . The ... 17 – 18 in Athens, Greece ... by pharmacy students and professionals, from which three ...
(Date:8/21/2014)... 2014  SI-BONE, Inc. ( San Jose, California ... use of the iFuse Implant System, ® a ... the sacroiliac (SI) joint, announced that Priority Health ( ... Lumbar Fusion Medical Policy No. 91590-R4 providing positive coverage ... states that the fusion procedure, which employs the iFuse ...
Breaking Medicine Technology:Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 2Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 3Professional Compounding Centers of America will award top poster-session winners at European Paediatric Formulation Initiative in Athens 2SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 2SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 3
... ... ... - Spasticity Affects a Significant Number of Post-Stroke ... , , ...
... Robbins & Myers, Inc. (NYSE: RBN ) announced today that its Board of Directors approved a regular cash dividend payment of $0.0425 per share. , ... , , ... ... The dividend is payable on May 7, 2010 to shareholders of record as of ...
Cached Medicine Technology:First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity 2First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity 3First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity 4First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity 5First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity 6First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity 7First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity 8First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity 9
(Date:8/21/2014)... New York, New York (PRWEB) August 21, 2014 ... allege the blood thinner caused patients to suffer uncontrollable ... in U.S. courts, Bernstein Liebhard LLP reports. According to ... August 14th in U.S. District Court, Easter District of ... who died due to a bleeding event that was ...
(Date:8/21/2014)... 21, 2014 Lauren Collura, a mother of ... “Back to the Boardwalk” Facebook sweepstakes. Lauren, her husband, and ... four-bedroom beachfront house in Lavallette beginning this Saturday. , ... Boardwalk” sweepstakes. Last year, Horizon Blue Cross Blue Shield of ... Superstorm Sandy and decided to make it a new summer ...
(Date:8/21/2014)... Steven Reinberg HealthDay Reporter ... of U.S. teens using sunscreen dropped nearly 12 percent in ... same time period, the number of teens using indoor tanning ... sunscreen increase the risk of skin cancers, including deadly melanomas, ... the overall percentage of teens who reported wearing sunscreen, from ...
(Date:8/21/2014)... August 21, 2014. Researchers have published a study ... of patients with motor complete spinal cord injury ... functioning at discharge and follow-up among patients with ... print on August 2 by the Archives ... Findings included small but significant differences in self-care ...
(Date:8/21/2014)... August 21, 2014 CarePoint Health ... Amish P. Patel, MD, and Sujoy Menon, MD, ... Dr. Patel and Dr. Menon to the community. ... of diagnostic imaging services to patients in Hudson ... Center, Christ Hospital and Hoboken University Medical Center. ...
Breaking Medicine News(10 mins):Health News:Xarelto Lawsuits Mount With New Filing in New York Federal Court, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuits Mount With New Filing in New York Federal Court, Bernstein Liebhard LLP Reports 3Health News:Xarelto Lawsuits Mount With New Filing in New York Federal Court, Bernstein Liebhard LLP Reports 4Health News:Fewer U.S. Teens Using Sunscreen, Study Finds 2Health News:Researchers examine impact of race and ethnicity in motor complete spinal cord injury 2Health News:Two Top Radiologists Join CarePoint Health 2
... Survey finds children and their children are ... March 27 (HealthDay News) -- Alzheimer,s care in the ... suggests. , Three in five so-called "sandwich" caregivers who ... said their children help with care duties, ranging from ...
... Unveiling a Secure, Convenient Solution to Identify Blood ... BIO-key International,Inc. (OTC Bulletin Board: BKYI), a leader ... a proud sponsor at the spring,2008 AABB Conference ... association formerly known as the American Association of,Blood ...
... response to the growing,demand for solutions to ... United,States, a group of entrepreneurs has established ... consulting,firm with over 25 years experience in ... implement pharmaceutical care, and,"Inspire Pharmacists to Practice ...
... free dental screening, DALLAS, March 27 ... Computer Services, Inc. (ACS) will,sponsor free dental education ... 28. The event will be held for pupils ... in Dallas, starting at 9:00 a.m., The ...
... study ... participants, MINNEAPOLIS, ... Minnesota Cancer Center and ClearWay Minnesota(SM) found that,since the Freedom to ... significantly reduced exposure to a,tobacco-specific cancer causing chemical., The study ...
... Up, and Changes Lives, One Smile at ... a Time via Operation Smile Partnership, CINCINNATI, March 26 ... to host an upcoming award show,Samantha Harris knows firsthand the importance ... has partnered with Oral-B Satin,Floss to not only show people how ...
Cached Medicine News:Health News:With Alzheimer's, It Takes a Family 2Health News:With Alzheimer's, It Takes a Family 3Health News:BIO-key(R) to Sponsor and Exhibit at AABB Spring Conference 2Health News:BIO-key(R) to Sponsor and Exhibit at AABB Spring Conference 3Health News:Tabula Rasa Strategies(TM), LLC, Announces Their Company Launch - A 'Clean Slate' Approach to the Practice of Pharmaceutical Care 2Health News:Tabula Rasa Strategies(TM), LLC, Announces Their Company Launch - A 'Clean Slate' Approach to the Practice of Pharmaceutical Care 3Health News:ACS Expands National Dental Outreach Program to Dallas 2Health News:U of M Study Provides First Scientific Evidence That the Freedom to Breathe Act is Creating Healthier Workplaces for Hospitality Employees 2Health News:U of M Study Provides First Scientific Evidence That the Freedom to Breathe Act is Creating Healthier Workplaces for Hospitality Employees 3Health News:Samantha Harris and Oral-B Satin Floss Partner to Share Smiles 2Health News:Samantha Harris and Oral-B Satin Floss Partner to Share Smiles 3
For the quantitative in vitro determination of Cholesterol in serum and plasma....
For the quantitative in vitro determination of Alkaline Phosphatase in serum or plasma....
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
Medicine Products: